Search results
Showing 1261 to 1275 of 2026 results for nice guidelines
NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Seladelpar for previously treated primary biliary cholangitis (TA1171)
Evidence-based recommendations on seladelpar (Livdelzi) for previously treated primary biliary cholangitis in adults.
Show all sections
well as encouraging shared decision making, are covered in the NICE clinical guideline on patient experience in adult NHS...
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)
NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Surgery for vaginal vault prolapse Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last updated...
The principles that guide the development of NICE guidance and standards.
Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)
Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.
Show all sections
Find out what guidance is being considered for development